Why the study?
Does enoxaparin reduce death or non-fatal recurrent myocardial infarction compared to unfractionated heparin in patients with STEMI treated with fibrinolysis?
Does enoxaparin reduce death or non-fatal recurrent myocardial infarction compared to unfractionated heparin in patients with STEMI treated with fibrinolysis?
An age- and renal-adjusted dosing strategy of enoxaparin is superior to unfractionated heparin for reducing death or recurrent MI in STEMI patients receiving fibrinolysis, despite a higher risk of major bleeding.
No takes yet. Share an insight, caveat, or question.
Supports adjusted enoxaparin over UFH in fibrinolysis-treated STEMI; extends LMWH evidence with bleeding trade-off.
White et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: